SEMA3E and diabetes mellitus: The Sema3E antibody titer increased after injection of the KLH-conjugated Sema3E peptide, and suppressed the infiltration of PlexinD1 positive cells, ameliorated visceral adipose tissue inflammation, and systemic glucose intolerance, suggesting that Sema3E peptide vaccine has therapeutic potential for obesity and diabetes [73].